All news

Pic:getty/andrewbrookes

Biogen releases long-term Aduhelm data

By Rachel Arthur

Biogen has announced new Phase 3 data showing that, after nearly 2.5 years of treatment, Aduhelm continued to reduce two key Alzheimer’s disease pathologies.

© GettyImages/Cecilie_Arcurs

Novartis inks contract manufacturing deal with Carisma

By Jane Byrne

Novartis continues down the third-party manufacturing route, as it secures an agreement with Carisma Therapeutics, a firm developing a cell therapy platform focused on engineered macrophage-based therapeutics.

Vibalogics Cuxhaven facility Germany © Vibalogics

Vibalogics adds capacity for virotherapy manufacturing in Germany

By Jane Byrne

Vibalogics, which was recently acquired by Swedish company, Recipharm, says the completion of its expansion project at its facility in Germany boosts capacity and further enhances its flexibility, minimizing time to clinic for customers.

pic:getty/zulotukhin

Flow Eighteen38 to double protein purification capacity

By Rachel Arthur

Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, has announced a €5m ($5.58m) investment into its protein production and biophysical characterization capabilities...

Pic:getty/naruedom

Moderna to build mRNA manufacturing site in Kenya

By Rachel Arthur

mRNA pioneer Moderna has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish an mRNA manufacturing facility in the country.

Pic:getty/yujisakai

Veristat expands in Europe with SLF acquisition

By Rachel Arthur

Clinical Research Organization Veristat has acquired SLF (Solutions for Life Sciences): adding capabilities to support biotech, pharmaceutical and medtech companies.

Pic:getty/coffeekai

Moderna initiates Phase 3 trial for RSV vaccine candidate

By Rachel Arthur

Moderna has initiated the Phase 3 portion of its pivotal respiratory syncytial virus (RSV) vaccine trial: looking towards its ultimate goal to combine the vaccine with its COVID-19 and flu boosters into a single dose booster.

Two of the new vaccine candidates target latent viruses. Pic:getty/artemisdiana

Moderna targets shingles in mRNA pipeline expansion

By Rachel Arthur

Moderna is expanding its mRNA pipeline with three new development programs: with vaccine candidates against herpes simplex virus (HSV), varicella-zoster virus (VSV) and a new checkpoint cancer vaccine.